Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 8/20 | 0.35 |
| ▸ | BLK | P51451 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29717615 | 1.00 | FLT3 (0.41) | FLT3BCDIN3DGAAEGFRBLK | |
| SCHEMBL19666286 | 0.88 | CNR2 (0.39) | STAT6MEN1USP2ALDH1A1CYP1A2 | |
| SCHEMBL19686002 | 0.85 | GAA (0.49) | BCDIN3DGAAEGFRKDRCAMK2D | |
| SCHEMBL29717716 | 0.85 | BRD4 (0.40) | STAT6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19666330 | 0.81 | EGFR (0.44) | EGFRKDRMEN1USP2ALDH1A1 | |
| SCHEMBL29717607 | 0.81 | EGFR (0.44) | EGFRKDRMEN1USP2ALDH1A1 | |
| SCHEMBL19666571 | 0.81 | EGFR (0.44) | EGFRKDRMEN1USP2ALDH1A1 | |
| SCHEMBL19666332 | 0.81 | EGFR (0.44) | EGFRKDRMEN1USP2ALDH1A1 | |
| SCHEMBL19685526 | 0.81 | EGFR (0.44) | EGFRKDRMEN1USP2ALDH1A1 | |
| SCHEMBL19685580 | 0.81 | MAPK9 (0.50) | EGFRKDRMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | claimed |
| EP-3464312-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | claimed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | claimed |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | claimed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | claimed |
| WO-2017210408-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | claimed |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3464312-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2017210408-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017210408-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | FLT3 3588/4885BCDIN3D 1217/4885GAA 570/4885 |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | FLT3 3588/4885BCDIN3D 1217/4885GAA 570/4885 |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | FLT3 3588/4885BCDIN3D 1217/4885GAA 570/4885 |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | FLT3 3588/4885BCDIN3D 1217/4885GAA 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.